Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

Last updated: July 4, 2025
Sponsor: Centre Hospitalier Universitaire de Besancon
Overall Status: Completed

Phase

N/A

Condition

Hematological Disorders

Stem Cell Transplant

Red Blood Cell Disorders

Treatment

Blood sample

Clinical Study ID

NCT03918343
P/2018/387
  • Ages 18-85
  • All Genders

Study Summary

This study is designed to assess the hypothesis that the lipopolysaccharide (LPS) activity index can be quantified early after transplantation, as well as the the PhosphoLipid Transfer Protein (PLTP) activity and these both biological variables are independent variables for predicting the risk of severe Graft versus Host Disease (GVHD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Hematologic malignancy in complete remission

  • Patients eligible for allogeneic hematopoietic cell transplantation from a relatedor unrelated donor and after myeloablative or non-myeloablative conditioning.

  • Regular follow-up in the center

Exclusion

Exclusion Criteria:

  • Treatment with a statin in progress

  • Umbilical cord blood transplantation

  • Hemoglobin level less than or equal to 8g / dl

  • Known chronic inflammatory bowel disease or gastroenteritis at the time ofinclusion.

  • Chronic enteropathy with Clostridium Difficile

Study Design

Total Participants: 95
Treatment Group(s): 1
Primary Treatment: Blood sample
Phase:
Study Start date:
September 06, 2019
Estimated Completion Date:
May 23, 2025

Connect with a study center

  • Centre Hospitalier Universitaire de Besançon

    Besançon, 25000
    France

    Site Not Available

  • Centre Hospitalier Universitaire de Nancy

    Nancy, 54 000
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.